IP Library Granted Patent US 8,906,392
Granted Patent B2
US 8,906,392 · App. 12/954,509 · Granted Dec 9, 2014

Nanocluster compositions and methods

Inventors: Cory J. Berkland (Lawrence, KS); Lianjun Shi (Bridgewater, NJ); Nashwa El Gendy (Cairo, EG); Carl Plumley (Little Rock, AR); Mark Bailey (Mountain View, CA)
Assignee: University of Kansas
A61K9/1688A61K9/1647A61K9/5123B82Y30/00A61K9/14A61K9/145A61K9/5192A61K9/1617A61K9/5153A61K9/5115A61K9/0075A61K9/1611
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,906,392
App. No.
12/954,509
Granted
Dec 9, 2014
Kind
B2
Abstract

Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm.

Claims (9)

1. A nanocluster comprising a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 μm to about 20 μm.

2. The nanocluster of claim 1 , wherein the mass median aerodynamic diameter is from about 0.5 μm to about 10 μm.

3. The nanocluster of claim 1 , wherein the mass median aerodynamic diameter is from about 3 μm to about 20 μm.

4. The nanocluster of claim 1 , wherein the active ingredient has solubility in water of less than 200 mg/ml.

5. The nanocluster of claim 1 , wherein the nanocluster comprises at least 50% nanoparticles by weight.

6. The nanocluster of claim 1 , wherein the active ingredient is an anti-inflammatory compound, a bronchodilator, an antimicrobial, a vaccine, an analgesic, an anxiolytic, a hypnotic, a vasodilator, a cytotoxic agent, an opiod, an anti-cancer agent, DNA, RNA, budesonide, vancomycin, moxifloxacin, mometazone, epinephrine, 13 C labeled urea, atropine, or diatrizoic acid.

7. The nanocluster of claim 1 , wherein the nanocluster is formulated into a dry powder, a suspension, an aerosol, a spray, a tablet, or a liquid.

8. The nanocluster of claim 1 , wherein the nanocluster is formulated together with a pharmaceutically acceptable carrier.

9. The nanocluster of claim 1 , wherein the nanoparticles consist essentially of the active ingredient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2011
From: BERKLAND, CORY J.; SHI, LIANJUN; EL GENDY, NASHWA; PLUMLEY, CARL; BAILEY, MARK
To: UNIVERSITY OF KANSAS
Reel/Frame 026353/0124 →
Continuity (8)
Continuation In Part PCTUS2009050565 · Jul 14, 2009
Continuation In Part 12261907 · Oct 30, 2008
Continuation In Part 12261873 · Oct 30, 2008
Division 11610986 · Dec 14, 2006
Provisional Application 60751172 · Dec 16, 2005
Provisional Application 61081034 · Jul 15, 2008
Provisional Application 61081037 · Jul 16, 2008
Related Publication 20110223203A1 · Sep 15, 2011